LIXT— LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Metric	FY2025	FY2024	FY2023	FY2022
General and administrative costs (includes $1,388,322 and $418,422 of stock-based compensation, respectively)	$4.9M+70.5%	$2.8M-32.1%	$4.2M+64.6%	$2.5M
Research and development costs	$255K-64.9%	$726K-19.1%	$898K-33.4%	$1.3M
Total costs and expenses	$5.1M+43.0%	$3.6M-29.8%	$5.1M-19.3%	$6.3M
Loss from operations	-$5.1M-43.0%	-$3.6M+29.8%	-$5.1M+19.3%	-$6.3M
Interest Income	$7K+4.8%	$7K-59.7%	$17K+56.2%	$11K
Interest Expense	-$9K+45.6%	-$17K-3.6%	-$16K-82.9%	-$9K
Realized loss on digital assets	-$904K	—	—	—
Foreign currency gain (loss)	$525+115.4%	-$3K-274.2%	$2K+157.9%	-$3K
Other income	$4K	—	—	—
Net loss	-$6.0M-67.6%	-$3.6M+29.5%	-$5.1M+19.4%	-$6.3M
Series B Convertible Preferred Stock 8% cumulative dividend	-$69K	—	—	—
Net loss attributable to common stockholders	-$6.1M-69.5%	-$3.6M+29.5%	-$5.1M+19.4%	-$6.3M
Earnings Per Share, Diluted	-$1.26+20.8%	-$1.59+40.2%	-$2.66+33.3%	-$3.99
Weighted Average Number of Shares Outstanding, Diluted	4.8M+115.2%	2.2M+17.4%	1.9M+21.1%	1.6M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.